# US 2024/0197904 A1 · Combination therapy for treating glioblastoma

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197904 A1
- Document ID: US20240197904A1
- Status: Published application
- Kind: A1
- Application number: 18/288,108
- Filed: 2022-04-25
- Published: 2024-06-20
- Earliest claimed: 2021-04-26
- Assignees: The Regents of the University of California
- Applicants: The Regents of the University of California
- Inventors: David A. Nathanson; Timothy F. Cloughesy; Elizabeth Fernandez
- Web page: https://patentgrep.com/patent/US20240197904A1

## CPC

- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 31/4725: containing further heterocyclic rings
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 47/6803: {Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates}
- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6851: {the antibody targeting a determinant of a tumour cell}
- A61P 35/00: Antineoplastic agents
- C07K 16/2827: {against B7 molecules, e.g. CD80, CD86}
- A61N 5/10: X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy (A61N5/01 takes precedence)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)

## Abstract

The present disclosure relates to a method of treating a glioblastoma by conjointly administering to a subject an antibody-drug conjugate comprising a BCL-xL inhibitor and a second therapy such as an alkylating agent, irradiation, or an MCL-1 inhibitor.

## Claims

### Claim 1

A method of treating a glioblastoma, comprising conjointly administering to a subject in need thereof an antibody-drug conjugate and a second therapy selected from an alkylating agent, irradiation, or an MCL-1 inhibitor, wherein the antibody-drug conjugate comprises a BCL-xL inhibitor.

### Claim 2 (depends on 1)

The method of claim 1, wherein the BCL-xL inhibitor is selected from A-1331852, WEHI 539, ABT-263, ABT-199, ABT-737, sabutoclax, AT101, TW-37, APG-1252, A1155463, gambogic acid, and a combination thereof.

### Claim 3 (depends on 2)

The method of claim 2, wherein the BCL-xL inhibitor is A-1155463 or A-1331852.

### Claim 4 (depends on 3)

The method of claim 3, wherein the BCL-xL inhibitor is A-1331852.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the antibody-drug conjugate comprises an antibody specific for B7H3 (CD276).

### Claim 6 (depends on 5)

The method of claim 5, wherein the antibody is enobilituzumab, omburtamab, or mirzotamab.

### Claim 7 (depends on 5)

The method of claim 5, wherein the antibody-drug conjugate is ABBV-155.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the second therapy is an MCL-1 inhibitor.

### Claim 9 (depends on 8)

The method of claim 8, wherein the MCL-1 inhibitor is selected from AT-101, MIK665/S64315, AMG176, AMG-397, A-1210477, VU661013, AZD5991, S63845 and a combination thereof.

### Claim 10 (depends on 9)

The method of claim 9, wherein the MCL-1 inhibitor is S63845 or S64315.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7)

The method of any one of claims 1-7, wherein the second therapy is selected from an alkylating agent and irradiation.

### Claim 12 (depends on 11)

The method of claim 11, wherein the second therapy is an alkylating agent.

### Claim 13 (depends on 12)

The method of claim 12, wherein the alkylating agent is temozolomide.

### Claim 14 (depends on 11)

The method of claim 11, wherein the second therapy is irradiation.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The method of any one of claims 1-14, wherein the glioblastoma is p53 wild type glioblastoma.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, comprising determining whether the glioblastoma is primed for apoptosis; and if the glioblastoma is primed for apoptosis, administering the antibody-drug conjugate and the second therapy.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the method induces release of cytochrome C from glioblastoma cells.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The method of any one of claims 1-16, wherein the method induces apoptosis of glioblastoma cells.
